RealSeq Biosciences

📍 Santa Cruz, United States🗓 Founded 2019👥 15 employees💰 Last funded Jun 2023
Biotechnology Research🌐 realseqbiosciences.com
Website LinkedIn
RealSeq develops groundbreaking RNA fragmentomics technology to allow real-time detection of disease dramatically improving diagnosis and treatment. RiboMarkers are next generation cell free (cf)RNA fragmentomics-based diagnostics that are dynamic reporters able to predict dissemination of disease. We are developing and commercializing a liquid biopsy platform for debilitating fungal pathogens such as Valley Fever that are currently poorly managed yet rapidly increasing due to factors such as climate change with global implications. Our core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy).
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in RealSeq Biosciences?
RealSeq Biosciences has 2 investors on record on gritt.io, 2 mid-stage.
When did RealSeq Biosciences last raise funding?
The most recent investment in RealSeq Biosciences recorded on gritt.io was in June 2023.
When was RealSeq Biosciences founded?
RealSeq Biosciences was founded in 2019.
What industry is RealSeq Biosciences in?
RealSeq Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is RealSeq Biosciences based?
RealSeq Biosciences is headquartered in Santa Cruz, United States.